Medtronic (MDT) DIvidends Date & History

Key Takeaways

• Medtronic pays a quarterly dividend of $0.72 per share, for an annualized payout of $2.88 and a dividend yield of roughly 3% to 3.2%.
• The company has increased its dividend for 49 consecutive years, placing it on the doorstep of becoming a Dividend King (50 consecutive years of increases).
• Medtronic is a member of the S&P 500 Dividend Aristocrats, reflecting decades of consistent, reliable payout growth.
• The payout ratio sits around 71% of trailing earnings but only about 36% of cash flow, suggesting the dividend is comfortably covered by free cash flow.
• Recent dividend increases have been modest (about 1.4% annually), making Medtronic more of an income stock than a fast-growing dividend stock.

Dividend Overview

Medtronic, one of the world's largest medical device companies, is best classified as a steady, income-oriented dividend stock rather than a high-growth payer. The company distributes its dividend on a quarterly schedule, with a current rate of $0.72 per share, equal to $2.88 on an annualized basis. Depending on the prevailing share price, the dividend yield has recently ranged between roughly 3.0% and 3.2% — well above the broader S&P 500 average.

For dividend investors, Medtronic's profile combines a competitive yield with exceptional longevity. Its 49-year track record of consecutive annual dividend increases signals a management team committed to returning capital to shareholders through economic cycles. While recent increases have been relatively small, the company's scale, diversified product portfolio, and recurring revenue from medical devices and consumables underpin a generally stable and predictable payout structure.

Dividend History and Growth

Medtronic's dividend history is among the most durable in the healthcare sector. The company has raised its payout for 49 consecutive years, making it a member of the S&P 500 Dividend Aristocrats — an index of companies that have increased dividends for at least 25 straight years. It now stands just one year away from qualifying as a Dividend King, a distinction reserved for companies with 50 or more consecutive years of increases.

Growth in the dividend has slowed in recent periods. Over the past five years, the dividend has compounded at roughly 4.1% annually, while the most recent increase was a modest 1.4%. Historically, however, the growth rate was much higher: the dividend has compounded at about 6% over the past decade and approximately 11% over the past two decades, according to company disclosures. This trajectory reflects Medtronic's evolution from a faster-growing innovator into a mature, cash-generative industry leader that prioritizes steady, dependable distributions.

Dividend Sustainability and Payout Ratio

The sustainability of Medtronic's dividend appears solid, though the payout ratio warrants context. On a trailing-twelve-month earnings basis, Medtronic pays out roughly 71% of its net income as dividends. This figure is elevated relative to faster-growing peers, but it is materially lower when measured against forward earnings estimates, which place the payout ratio in the mid-to-high 40% range.

More importantly, the dividend is well covered by cash generation. The cash-flow payout ratio is approximately 36%, meaning only about a third of the company's free cash flow is needed to fund the dividend. Medtronic has also been improving its free cash flow, which has helped bring the earnings-based payout ratio down from higher levels. A strong balance sheet and diversified, recurring revenue streams across cardiac, surgical, neuroscience, and diabetes care further support the view that the dividend is maintainable and can continue to grow at a modest pace.

Dividend Compared to Industry Peers

Within the large-cap medical device space, Medtronic's yield stands out as one of the highest. Rivals such as BSX (Boston Scientific), SYK (Stryker), and ABT (Abbott Laboratories) generally pay little or modest dividends, often yielding below 2%, as they reinvest more aggressively into growth. By contrast, MDT offers a yield of roughly 3% or more, comparable to diversified healthcare giants such as JNJ (Johnson & Johnson).

This positioning reflects Medtronic's maturity: it generates substantial cash flow and returns a meaningful portion to shareholders rather than pursuing rapid expansion. For investors comparing yield within the sector, Medtronic offers an above-average income profile paired with one of the longest dividend growth streaks in healthcare.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can also help identify dividend stocks, income-focused investments, trending names, breakout candidates, and emerging market opportunities far more efficiently than manual screening. For investors seeking to compare dividend profiles, yields, and growth streaks across the market, the AI Screener offers a practical starting point for building a focused watchlist.

Is This Stock Attractive for Dividend Investors?

Medtronic is most likely to appeal to income-oriented and conservative, long-term dividend investors who prioritize reliability and yield over rapid payout growth. With a yield of roughly 3% and a nearly five-decade streak of annual increases, the stock offers a combination of current income and dividend dependability that is uncommon in the medical device industry.

Dividend growth investors, however, should note that recent increases have been small — around 1.4% in the latest raise — meaning the dividend may not keep pace with inflation in the near term. The elevated trailing earnings payout ratio also leaves less cushion for aggressive future hikes compared with lower-payout peers. That said, strong free cash flow coverage, a resilient balance sheet, and diversified recurring revenue provide a solid foundation for the dividend's continued payment and gradual growth. As with any equity, total returns will also depend on share-price performance, and investors should weigh these income characteristics against their own financial objectives and risk tolerance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations